Preview Mode Links will not work in preview mode

May 5, 2023

Featuring perspectives from Drs Andrew J Armstrong and Rana R McKay, including the following topics:

  • Introduction (0:00)
  • Intensification of endocrine therapy: Emerging role in nonmetastatic disease; choice of androgen deprivation therapy (3:31)
  • Management of castration-resistant M0 disease; PROTACs, CDK4/6 inhibitors and other new endocrine approaches (16:18)
  • Hormone-sensitive metastatic disease — Choice of antiandrogen (26:48)
  • Castration-resistant metastatic disease (37:06)
  • Genomic evaluation; PARP inhibitors for metastatic disease (46:24)
  • Ideal sequencing of PARP inhibitors; management of associated side effects (55:21)
  • Biomarker testing; MSI-high disease; TKIs with immunotherapy; bispecific antibodies? (59:42)

CME information and select publications